|
|
|
xtalks.com, webinar
Tuesday, April 12, 2022 | 11am EDT (NA) / 4pm BST (UK) / 5pm CEST (EU-Central)
Who Should Attend?- QA and QC Managers
- Operations Managers
- Regulatory Compliance Managers
- Chemistry, Manufacturing and Controls (CMC) Managers
- Consultants
What You Will Learn- Updated USP <795>, <797> and <800> Regulations
- Benefits of onsite pharmacy compounding
- How to choose a clinical research organization (CRO) with an adequate compounding facility and properly trained staff
- Tips for making a Phase I study successful
|
|
|
|
|
|
Organized by:
|
|
xtalks.com |
|
Invited Speakers:
|
|
SpeakerJennifer Foster, Pharm D, RP, Authorized Nuclear Pharmacist, Director of Global Pharmacy Operations, CelerionDr. Foster is the Director of Global Pharmacy Operations at Celerion and is located at the Lincoln, Nebraska site. She is responsible for overseeing all three Celerion pharmacies as well as ADME studies from a pharmacy, licensing and total radioactivity reporting perspective. She has worked on over 100 ADME studies with all varieties of formulations and challenges. Dr. Foster graduated from the University of Nebraska Medical Center in 2001 with a Pharm D. In 2016, she completed the Authorized Nuclear Pharmacist program from Purdue University. She joined MDS Pharma Services in August of 2001 in the pharmacy as a Clinical Research Pharmacist. She transitioned to Celerion in 2010.
|
|
|
|
|
|
Deadline for Abstracts:
|
|
na
|
|
|
|
|
|
Registration:
|
|
https://xtalks.com/webinars/compounded-drugs-onsite-pharmacy-compounding-for-phase-i-clinical-studies/
|
|
E-mail:
|
|
shunte@xtalks.com
|
|
|
|
|
|
|
|